Analysts forecast that Sarepta Therapeutics Inc (NASDAQ:SRPT) will announce ($0.47) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Nine analysts have made estimates for Sarepta Therapeutics’ earnings, with estimates ranging from ($1.24) to ($0.21). Sarepta Therapeutics reported earnings of ($1.15) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 59.1%. The firm is scheduled to announce its next earnings results on Wednesday, July 18th.
On average, analysts expect that Sarepta Therapeutics will report full year earnings of ($1.22) per share for the current year, with EPS estimates ranging from ($1.61) to ($0.90). For the next fiscal year, analysts anticipate that the company will report earnings of $0.15 per share, with EPS estimates ranging from ($0.88) to $1.18. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Sarepta Therapeutics.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Thursday, May 3rd. The biotechnology company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.23). The firm had revenue of $64.60 million for the quarter, compared to analysts’ expectations of $65.31 million. Sarepta Therapeutics had a negative return on equity of 24.68% and a negative net margin of 83.88%. The company’s revenue for the quarter was up 295.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.57) earnings per share.
Several analysts have issued reports on the company. Credit Suisse Group reaffirmed a “hold” rating and set a $81.00 target price on shares of Sarepta Therapeutics in a research report on Monday, March 12th. BTIG Research assumed coverage on Sarepta Therapeutics in a research report on Friday, June 15th. They set a “buy” rating and a $120.00 target price on the stock. Leerink Swann increased their target price on Sarepta Therapeutics from $88.00 to $121.00 and gave the company an “outperform” rating in a research report on Tuesday, May 15th. BidaskClub cut Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, March 29th. Finally, Goldman Sachs Group increased their target price on Sarepta Therapeutics from $84.00 to $127.00 and gave the company a “buy” rating in a research report on Friday, May 18th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $126.50.
Shares of Sarepta Therapeutics opened at $135.29 on Friday, according to Marketbeat. The company has a current ratio of 13.37, a quick ratio of 12.28 and a debt-to-equity ratio of 0.55. The firm has a market cap of $8.89 billion, a price-to-earnings ratio of -82.49 and a beta of 1.34. Sarepta Therapeutics has a 12-month low of $32.80 and a 12-month high of $176.50.
In other Sarepta Therapeutics news, Director Richard Barry sold 75,000 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, June 27th. The stock was sold at an average price of $130.34, for a total transaction of $9,775,500.00. Following the completion of the sale, the director now owns 3,170,432 shares of the company’s stock, valued at approximately $413,234,106.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 7.90% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. LPL Financial LLC purchased a new position in shares of Sarepta Therapeutics during the 4th quarter valued at about $643,000. TimesSquare Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 3.5% during the 4th quarter. TimesSquare Capital Management LLC now owns 491,250 shares of the biotechnology company’s stock valued at $27,333,000 after buying an additional 16,800 shares during the last quarter. Delek Group Ltd. purchased a new position in shares of Sarepta Therapeutics during the 4th quarter valued at about $2,056,000. Xact Kapitalforvaltning AB purchased a new position in shares of Sarepta Therapeutics during the 4th quarter valued at about $345,000. Finally, Handelsbanken Fonder AB purchased a new position in shares of Sarepta Therapeutics during the 4th quarter valued at about $1,196,000. Institutional investors and hedge funds own 86.27% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.